Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 273

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders

Open access
Lauffer, Marlen C., van Roon-Mom, Willeke, Aartsma-Rus, Annemieke, N = 1 Collaborative·2024·Communications Medicine

Abstract

Antisense oligonucleotides (ASOs) are incredibly versatile molecules that can be designed to specifically target and modify RNA transcripts to slow down or halt rare genetic disease progression. They offer the potential to target groups of patients or can be tailored for individual cases. Nonetheless, not all genetic variants and disorders are amenable to ASO-based treatments, and hence, it is important to consider several factors before embarking on the drug development journey. Here, we discuss which genetic disorders have the potential to benefit from a specific type of ASO approach, based on the pathophysiology of the disease and pathogenic variant type, as well as those disorders that might not be suitable for ASO therapies. We further explore additional aspects, such as the target tissues, intervention time points, and potential clinical benefits, which need to be considered before developing a compound. Overall, we provide an overview of the current potentials and limitations of ASO-based therapeutics for the treatment of monogenic disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s43856-023-00419-1

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 77 references

Cited by

See all 273

Metadata

Authors
Lauffer, M. C., van Roon-Mom, W., Aartsma-Rus, A., & Collaborative, N. =. 1.
Venue
Communications Medicine
Published
2024-01-05
Volume
4
Issue
1
Pages
6-6
ISSN
2730-664X (ISSN-L)
OpenAlex
W4390603683
Cited by
273
References
77
FWCI
31.72
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. https://app.cochat.ai/papers/10.1038/s43856-023-00419-1
The paper
Lauffer, M. C., van Roon-Mom, W., Aartsma-Rus, A., & Collaborative, N. =. 1. (2024). Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. Communications Medicine. https://doi.org/10.1038/s43856-023-00419-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.